IDA FOUNDATION & IDA ARV BV Partners in Affordable Healthcare Connie van Marrewijk IDA Foundation.

Slides:



Advertisements
Similar presentations
Quality Assurance Processes for TB Drugs. GDF Quality Assurance Processes.
Advertisements

Quality Assurance Policy RHSC, SSWG Addis Ababa, Ethiopia 21 June 2011 Morten Sorensen, UNFPA PSB.
Policy on Quality Assurance for Single and Limited- Source Pharmaceuticals Nairobi, Kenya, 20 – 24 February 2006.
Dr. M. Iwasaki 1 Asian Multinational Clinical Trials - Current Status & Future Direction - Dr.Masaru IWASAKI PR Japan Operations Center Aventis Pharma,
MeTa, Solwezi 27 August,2013.  A branded- name drug product is originally discovered and developed by a pharmaceutical company.  Branded-name drugs.
Access to Medicines: what should the industry contribute? Part II: Supply Chain & Delivery Systems - The Last Mile Challenge EFPIA 18 th September 2013.
Good Manufacturing Practices Guilin, PRC Dr AJ van Zyl for Quality Assurance and Safety: Medicines Medicines Policy and Standards Health Technology and.
Prequalification and Quality Monitoring of anti-malaria products Andre van Zyl, M. Pharm. Project Manager Health Technology and Pharmaceuticals Cluster,
UNICEF Medicines Supply Strengthening WHO Technical Briefing Seminar on Essential Medicines and Health Products Tuesday 29 October 2013 Technical Specialist.
Slide 1 of 19D.K. Mubangizi, Dar Es Salaam Sept Training Workshop for Evaluators from National Medicines Regulatory Authorities in East African Community.
Update by IDA Foundation Leontien Ruttenberg MSc MBA.
TBS Meeting Geneva, November 2011 Global Fund Policies and Reporting on Procurement of Health Products WHO/UNICEF Technical Briefing Seminar on Essential.
Training Course on Managing Medicines and Pharmaceutical Supplies for Tuberculosis.
Supply Chain Management System Project The Partnership for Supply Chain Management March 2006.
PREQUALIFICATION General overview and procedures Maija Hietava M.Sci.Pharm Quality Assurance and Safety: Medicines, Medicines Policy and Standards, Health.
PREQUALIFICATION General overview and procedures
Structure of Dossier of Medicinal Product- Q part
NATIONAL DRUG AUTHORITY - UGANDA | Slide 1 of February 2010, Geneva, Switzerland How the African NMRAs are benefiting from the WHO medicines prequalification.
Documentation –Part 2 Basic Principles of GMP Pharmaceutical Quality,
World Health Organization
Unlicensed Medicines in Paediatrics Is there a problem ? Scottish Neonatal and Paediatric Pharmacist Group National Paediatric Pre- Registration Pharmacist.
Quality Control Testing in Procurement Helene Möller, M.Pharm, PhD Interregional Seminar for Quality Control Laboratories involved in WHO Prequalification.
Technology Transfer & Quality
PROCUREMENT SUPPORT SERVICE WHO/UNICEF Technical Briefing Seminar on Essential Medicines Policies, November 1 st -5 th 2010 Mariatou Tala Jallow, Manager,
Inspection Issues in the Analytical Laboratory: An FDA Perspective Yvonne McKnight Chemist US Food and Drug AdministrationPhone: x
Family Health International Kenneth F. Schulz, PhD, MBA Science for Global Action and Impact.
Sultan Ghani WHO Prequalification Programme of Priority Essential Medicines, October 2010, Abu Dhabi, U.A.E. Dossier Requirements for Generic Medicines.
Options for national/regional production of generic medicines Wilbert Bannenberg, MD MPH Lesotho TRIPS workshop 14 Aug 2014.
QUALITY REPRODUCTIVE HEALTH SUPPLIES Dr Hans V. Hogerzeil Director Essential Medicines & Pharmaceutical Policies.
RHSC Meeting Kampala, May 2010 Quality for Medicines The Global Fund approach Sophie Logez Manager, QA and Data Quality Pharmaceutical Management.
1 TG Dekker – WHO, UkraineOctober 2005 Introduction to Dossier Requirements and Guidelines within the Prequalification Project (quality part) World Health.
Important informations
Paula Munderi Department of Essential Drugs and Medicines Policy World Health Organization Access to essential medicines for HIV/AIDS - update on WHO activities.
OR “READ THE FINE PRINT PLEASE!”
Progress to date and Plans for Year 5 Overcoming HIV/AIDS epidemic in Ukraine Programme supported by the Global Fund 11 th Stakeholders’ meeting 22 nd.
Update on prequalification of medicines Dr Lembit Rägo Quality Assurance and Safety: Medicines Medicines Policy and Standards Health Technology and Pharmaceuticals.
Experience with common basket for ARV procurement Tanzania Emma Lekashingo Msuya.
Quality Assurance for pharmaceutical products in international procurement Approach of major donors and procurers Core presentation prepared by Sophie.
2004: 39.4 (35.9 – 44.3) million Western & Central Europe [ – ] North Africa & Middle East [ – 1.5 million] Sub-Saharan.
Assessment of Interchangeable Multisource Medicines BCS-Biowaivers - Template Dr. Henrike Potthast Training workshop: Assessment of.
1 WHO/UNICEF Technical Briefing Seminar on Essential Medicines Policies Tuesday 1 November 2011 Technical Specialist Henrik K.Nielsen, Medicines and Nutrition.
From 3by5 to Universal Access to HIV/AIDS Treatment: AMDS Technical Briefing Seminar for Consultants on Procurement and Supply Management for HIV, TB and.
Slide 1 of 10D.K. Mubangizi, Dar Es Salaam Sept Training Workshop for Evaluators from National Medicines Regulatory Authorities in East African Community.
Managing Procurement and Logistics of HIV/AIDS Drugs and Related Supplies By Yvonne Nkrumah Legal Counsel, Ghana Food and Drugs Board.
PQP-overview & update January Prequalification of Medicines Overview & update Wondiyfraw Z. Worku WHO Prequalification of Medicines Programme Assessment.
Philippe Duneton11 February 2009 Deputy Executive Secretary 5th Consultative Stakeholder Meeting UN Prequalification of Diagnostics, Medicines & Vaccines.
WHO Prequalification of Medicines: a gateway to the global pharmaceutical market Introduction 28 June 2014, Shanghai Milan Smid.
UNICEF Medicines Supply Strengthening WHO/UNICEF Technical Briefing Seminar on Essential Medicines Policies Tuesday 30 October 2012 Technical Specialist.
TBS Meeting Geneva, November 2010 Procurement and Supply Management Policies WHO/UNICEF Technical Briefing Seminar on Essential Medicines Policies, November.
Achievements and impacts of WHO prequalification to date MSF perspective Carine Werder MSF international pharmacist coordinator Geneva, 11 th February.
Drug Management of Second-line anti-TB drugs through the Green Light Committee mechanism for programmes funded by the Global Fund to Fight Against AIDS,
3rd WHO Prequalification Stakeholders Meeting :Diagnostics 3rd Stakeholders Meeting on Prequalification Geneva, 4th February 2008 Update on Prequalification.
Dr. Pogány - WHO, Shanghai 1/35 Workshop on Quality Assurance and GMP of Multisource HIV/AIDS medicines János Pogány, pharmacist, PhD, consultant.
Leveraging the prequalification process for national regulatory decision making Fimbo, A. M Tanzania Food and Drugs Authority.
Affordable healthcare Product Selection for TB, Malaria and HIV/AIDS Key issues for procurement IDA HIV/AIDS Group, Nienke Gruppelaar.
UNITAID actions and main achievements Investing in the quality of medicines XVII International AIDS Conference Satellite Forum WHO – Essential Medicines.
Tanzania, August 2006 Dr. Barbara Sterzik, BfArM, Bonn 1 Bioequivalence dossier requirements for the prequalification project WHO Training Workshop.
Ensuring quality of medicines procured with Global Fund resources HIV AIDS conference Satellite on Essential Medicines for HIV AIDS Mexico 6 August 2008.
Documentation –Part 2 Basic Principles of GMP Pharmaceutical Quality,
Quality Assurance and Quality Control in Generics
The WHO Prequalification of Medicines Programme Capacity building agenda Dr Milan Smid.
Health Supply Chain Management: Session 6: Facilities, Staffing and Procurement Ghana Nursing Schools.
Prequalification of essential medicines Technical Briefing Seminar
Essential Drugs and Medicines Policy (EDM) World Health Organization
Prequalification of essential medicines
Global Drug Facility: Providing Access to Medicines and Commodities for Tuberculosis Thomas Moore Manager GDF Geneva, 19 November 2009.
Product selection issues
Prequalification of HIV/AIDS products and manufacturers
Understanding Drug Labels
SID & GP MINPROMTORG OF RUSSIA Corporate Communication Center
Presentation transcript:

IDA FOUNDATION & IDA ARV BV Partners in Affordable Healthcare Connie van Marrewijk IDA Foundation

AGENDA   INTRODUCTION IDA FOUNDATION   IDA ARV BV   SUPPLY OF MEDICINES   QA/QC SYSTEM   PAPERWORK   CONCLUSION

IDA FOUNDATION The world’s leading not-for-profit supplier of medicines and medical supplies to developing countries “To provide high quality essential drugs and medical supplies at the lowest possible price to non-profit health care organisations in developing countries.”  one-stop shop for essential drugs, diagnostics & supplies

ESTABLISHMENT IDA ARV BV Jan 2004 Focus on the specific issues & challenges related to ARV & HIV/AIDS medical supplies procurement Centralisation knowledge in the following areas:  patents & registration  logistics  sourcing  one-stop shop for ARV’s, OI’s & Diagnostics

ARV PROJECTS ARV’s are now routinely supplied to projects in over 24 countries Global Fund Cambodia El Salvador Other Projects Ethiopia Burundi Georgia Eritrea Ghana East Timor Haiti Kenya Honduras Guinee-Eq. Ivory Coast Uzbekistan Nicaragua Zimbabwe Lesotho Guinee Moldova Sudan TanzaniaMozambique Peru Úkraine

SUPPLY of ARV’s ARV projects often demand a mixture of generics and branded products GENERICBRANDED Produced in developing worldProduced in Western Europe / US Independent QA & QC QA &QC by manufacturer FDC’s available Combination of different tablets

QA\QC at IDA Standardised & Controlled QA/QC system resulting in high quality IDA medicines To filter out substandard medicines No experience with counterfeit medicines Note: IDA label copied (2 cases)

QA / QC Verify WHO Pre-qualification doc Check GMP status GMP audit by IDA pharmacist Qualification Manufacturer Qualification Product Approval Product Specification Check stability (BE) data and shelf life Verification certificate of pharmaceutical product Check packing, labelling & leaflets Verification quality of samples* Check additional requirements Product Batch Control Physical control of batch Verification API Control certificates of analysis At –random chemical analysis Verifying product stabilities Trend analysis * By independent contract laboratory Quality AssuranceQuality Control*

QA / Qualification manufacturer GMP o oManufacturing process o oEquipment and maintenance o oPlant design and environment o oPersonnel and training o oDocumentation Handling and storage condition o oSpecial shipment for keep cool items (IDA has 4 classes from *a to ***) o oControlled temperature in warehouses (IDA and client) o oGood dispensing practice

QA / Qualification product Design of the product o oDrug formulation o oActive ingredient (API) o oInactive ingredient o oBio-availability (rate and extend of absorption) o oAssessments of CRO’s o oStability o oPackaging: Immediate and External o oLabelling & Information leaflet o oDocumented evidence o oValidated methods of control & production o oRegistration dossier

QC / Product batch control Physical control   Verification API   Control certificate of analysis   At random chemical analyses   Manufacturer – site combination check   Verifying product stabilities   Trend analyses   Document number   Authorisation signatures   Referral to Pharmacopeia (eg. UK or US)   Any added substances   Form and strength

IDA Product presentation Label   International Nonproprietary Name (INN)   Strength   Dosage form   Route of administration (parenterals)   Storage conditions   Batch mfd exp   Packsize   Other

Product presentation Shipper cartons   No product labels (to prevent theft)   IDA code number, batch number and exp date   Strong quality

GUIDELINES IDA ARV BV compliant with WHO guidelines Antiretrovirals must: Have been accepted by the WHO prequalification project; or a.Have been authorized for consumption by a stringent regulatory authority; or b.Have been authorized by the NDRA in the recipient’s country. Option c. is applicable only until April 2005, pending a Global Fund Board decision

HANDLING PAPERWORK Expertise and experience for required export documentation e.g.: –Packing List –Certificates of Analysis –Airway bill –Required documentation for tax exemptions –Registration requirements in countries Service –Language labelling & leaflets –INCO Terms –Payment conditions –Currency –Pricing requirements (e.g. Clinton Foundation)

CONCLUSION One stop shop Standardised 3-step QA/QC system Knowledge about registration possibilities Experience & Expertise PLEASE NOTE THAT IDA FOUNDATION ALSO HAS AN EXTENDED RANGE FOR OPPORTUNISTIC INFECTIONS,TB & MALARIA

BURUNDICAMBODIA EAST TIMOR EL SALVADOR ERITREAETHIOPIAGEORGIAGHANAGUINEEGUINEE-EQ.HAITI HONDURAS HONDURAS IVORY COAST KENYALESOTHOMOLDOVAMOZAMBIQUENICARAGUAPERUSUDANTANZANIAUKRAINE UZBEKISTANZIMBABWE